Last reviewed · How we verify
WBI-1001
At a glance
| Generic name | WBI-1001 |
|---|---|
| Sponsor | Welichem Biotech Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (PHASE3)
- A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks (PHASE2)
- Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream (PHASE2)
- Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis (PHASE1, PHASE2)
- Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WBI-1001 CI brief — competitive landscape report
- WBI-1001 updates RSS · CI watch RSS
- Welichem Biotech Inc. portfolio CI